×
About 258 results

ALLMedicine™ Alopecia Universalis Center

Research & Reviews  82 results

Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Tw...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305636
International Journal of Environmental Research and Publi... Borriello G, Ianniello A et. al.

Jul 25th, 2021 - Alopecia Universalis (AU) is the most severe form of Alopecia Areata and is caused by cytotoxic T-cells reacting with follicular autoantigens, producing complete loss of scalp and body hair. Alemtuzumab is a highly efficacious monoclonal antibody ...

T-Cell-Driven Fibroinflammation Inducing Follicular Dedifferentiation in Alopecia Areat...
https://doi.org/10.1097/DAD.0000000000001992
The American Journal of Dermatopathology; Kossard S, Sheriff T et. al.

Jun 17th, 2021 - The definition of IgG4-related diseases incorporates a broad range of systemic diseases particularly a subset dominated by fibroinflammation. CD4+cytotoxic T cells have emerged as the major driving force for the fibroinflammation, and the pathogen...

Prediction of the Risk of Alopecia Areata Progressing to Alopecia Totalis and Alopecia ...
https://doi.org/10.1159/000515764
Dermatology (Basel, Switzerland); Zhang T, Nie Y

May 19th, 2021 - Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. Although there is an increased understanding of AA pathogenesis and progress in its treatments, the outcome of AA patients remains unf...

Alopecia areata is not a risk factor for heart diseases: A 10-year retrospective cohort...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104430
PloS One; Lee H, Kim YC et. al.

May 8th, 2021 - Alopecia areata (AA) is an autoimmune skin disease caused by chronic inflammation of hair follicles. Chronic inflammatory skin diseases such as psoriasis and lupus erythematosus can increase the risk of cardiovascular diseases. However, the relati...

Alopecia universalis: a patient's perspective of the cumulative life course impairment.
https://doi.org/10.1111/ced.14596
Clinical and Experimental Dermatology; Burns LJ, Flanagan KE et. al.

Mar 20th, 2021 - Alopecia universalis: a patient's perspective of the cumulative life course impairment.|2021|Burns LJ,Flanagan KE,Pathoulas JT,Ellison A,Mesinkovska N,|

see more →

Clinicaltrials.gov  4 results

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
https://clinicaltrials.gov/ct2/show/NCT03315689

Aug 1st, 2019 - This study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution in patients with Alopecia Universalis and Alopecia Totalis. Concentrations of ATI-50002 in the blood and skin will be ...

Alopecia Areata Registry
https://clinicaltrials.gov/ct2/show/NCT00069589

May 14th, 2019 - Alopecia areata is a condition in which hair is lost either from part of the scalp, all of the scalp, or the entire body, and it affects 1% to 2% of the population. It is thought to be an autoimmune disease and in some cases the disease is heredit...

A Study of Secukinumab for the Treatment of Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT02599129

Nov 30th, 2017 - Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body. Alopecia areata is an autoimmune skin disease, which means that the immune system is recognizing ...

Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis
https://clinicaltrials.gov/ct2/show/NCT01314495

Nov 14th, 2012 - Alopecia Areata is a common autoimmune disease, affecting 1% of the general population resulting from autoimmune attack on the hair follicles and usually presents with patchy hair loss. One third of these patients will experience spontaneous remis...

see more →

News  17 results

Anthralin shows promise as second-line agent for pediatric alopecia areata
https://www.mdedge.com/pediatrics/article/189807/dermatology/anthralin-shows-promise-second-line-agent-pediatric-alopecia
Jill D. Pivovarov

Nov 29th, 2018 - Given its limited systemic toxicity, topical anthralin is an acceptable second-line treatment option for pediatric alopecia areata (AA), according to Sean Z. Wu, MD, of the department of dermatology, University of Cincinnati, and his associates.

JAK Inhibitors Promising for Alopecia Areata
https://www.medscape.com/viewarticle/902077

Sep 17th, 2018 - PARIS — Two investigational oral Janus kinase (JAK) inhibitors are safe and effective for patients with moderate to severe hair loss, according to 24-week interim findings from a randomized, double-blind, placebo-controlled, multicenter phase 2 tr...

JAK Inhibitors Promising for Alopecia Areata
https://www.staging.medscape.com/viewarticle/902077

Sep 17th, 2018 - PARIS — Two investigational oral Janus kinase (JAK) inhibitors are safe and effective for patients with moderate to severe hair loss, according to 24-week interim findings from a randomized, double-blind, placebo-controlled, multicenter phase 2 tr...

JAK inhibitors emerge as promising alopecia treatment
https://www.mdedge.com/familymedicine/article/174331/hair-nails/jak-inhibitors-emerge-promising-alopecia-treatment
Dermatology News; Doug Brunk

Sep 9th, 2018 - LAKE TAHOE, CALIF. – After Brett King, MD, PhD, and his wife and collaborator, Brittany G.

JAK inhibitors look good for severe alopecia areata treatment
https://www.mdedge.com/familymedicine/article/157463/dermatology/jak-inhibitors-look-good-severe-alopecia-areata-treatment
Pediatric News; Catherine Cooper Nellist

Jan 31st, 2018 - Janus kinase inhibitors look promising in the treatment of severe alopecia areata, particularly in adolescents, said Lucy Yichu Liu, MD, and Brett Andrew King, MD, of Yale University, New Haven, Conn. Standard medical therapies for alopecia areata.

see more →